|
by Celia Farber
December
05, 2021
from
CeliaFarber Website
Show 1223
Deaths,
158,000 Adverse
Events
in 90 Days Post
EUA Release.
The most Shocking Document Release
of the Last 100
years...
I want to tell you
urgently that I am sitting here, as shocked as I can remember being,
since I began reporting on pharmaceutical and government/
pharmaceutical predation in 1987/1988, at a rock magazine called
SPIN.
I've spent most of my
life shocked, often disoriented, wondering if I can believe my own
eyes, and trying to square the countless attacks on my own sanity
with what appears to be the impossibly dark truth.
For years I processed the
relentless violence as some kind of possibility that I had missed
something. I don't anymore. Everybody who has failed to oppose this
is complicit in mass murder.
There are not "two
sides."
Pfizer itself can explain
exactly why all the people dropping dead have died, but they felt it
should be hidden for 55 years, so they could continue to murder and
maim without interference.
The mass media is the
engine of the catastrophe, the sine qua non.
Most smoking guns are not really smoking guns, but this one is.
A group called "Public
Health and Medical Professional for Transparency Documents",
sued
the FDA for the release of
Pfizer's documents concerning adverse events from their Covid
"vaccine", which Pfizer fought to have concealed 55 years, but a
courageous judge ordered them released anyway...
They wrote on their
website:
"Four days after the
Pfizer vaccine was approved for ages 16+, we submitted a Freedom
of Information Act Request to the FDA for all of the data within
Pfizer's COVID-19 vaccine biological product file.
We have now sued the
FDA for not releasing the data.
Click
HERE for court documents and
for productions of Pfizer's documents from the FDA..."
My God...
In the 90 days following EUA release of the "vaccine" they recorded
1223 deaths, and 158,000 adverse reactions, including fetal deaths,
spontaneous abortions and more.
They call this, in their
encrypted, trans-human Pharma-lingo, the "post marketing
experience." (Read, '5.3.6
Cumulative Analysis of Post-Authorization Adverse Event - Reports of
Pfizer-07302048 (Bnt162b2) Received through 28-Feb-2021')
Whose experience?
Pfizer's, or the
dead...?
I failed to catch on to
this when it was released a few days ago, for which I apologize.
Mark Crispin Miller
sent it out today and I realized I'd missed something incredibly
important.
I opened
the document and began to read, as
my mind short-circuited.
One thinks one has seen
it all, but no.
I'd heard Alex Jones apoplectically reporting on it this week
but for some reason I still didn't drop what I was doing and go to
it.
Mike Adams
reported comprehensively on it
here.
Normally I write prose, sentences, but now I am dropping a massive
boulder of words, a sheer word cloud, so you can have a visual sense
of the extent of the "adverse events" Pfizer outrageously and
blithely calls "...of special interest."
(Note: The
events are in fact a master list of potential events that encompass
all adverse events they have ever collected. See update and
correction
here.)
These "events" have never been "of special interest" to the
protected class of mass media vaccine propagandists, but they are
REAL. They are now here in black and white, from Pfizer's own
documents.
They mirror exactly
what everybody who has been trying to sound the alarm has ever
said...
There is no mystery
anymore...
Anybody who tells you
these "vaccines" are safe is somewhere between
hypnotized, dishonest, idiot and malicious.
As these Pfizer documents
lay bare, our bodies are nothing but their field of sadistic
experimentation, their wealth gain, their total self-appointed right
to destroy life, while raking in billions, maybe trillions, and even
guilt-tripping their endless victims for not promoting "vaccines"
once they have been crippled.
Even the dead are
expected to promote vaccines from the grave, via their surviving
loved ones.
Yet you are an "anti-vaxxer."
And this is a fate worse, they make clear, than death.
But no need to believe "anti-vaxxers" anymore - here's
the data from
Pfizer, of everything these predators
have "observed" in their victims, whose lives they are ostensibly so
insistent upon "saving" and who were healthy before the shots, but
spellbound by fear, and sacrificed by an unspeakably
cold-blooded media:
APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST
1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase
increased;Acoustic neuritis;Acquired C1 inhibitor
deficiency;Acquired epidermolysis bullosa;Acquired epileptic
aphasia;Acute cutaneous lupus erythematosus;Acute disseminated
encephalomyelitis;Acute encephalitis with refractory, repetitive
partial seizures;Acute febrile neutrophilic dermatosis;Acute
flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute
haemorrhagic oedema of infancy;Acute kidney injury;Acute macular
outer retinopathy;Acute motor axonal neuropathy;Acute
motor-sensory axonal neuropathy;Acute myocardial
infarction;Acute respiratory distress syndrome; [note: that
sounds like "Covid 19."]
Acute respiratory
failure;Addison's disease;Administration site
thrombosis;Administration site vasculitis;Adrenal
thrombosis;Adverse event following
immunisation;Ageusia;Agranulocytosis;Air embolism;Alanine
aminotransferase abnormal;Alanine aminotransferase
increased;Alcoholic seizure;Allergic bronchopulmonary
mycosis;Allergic oedema;Alloimmune hepatitis;Alopecia
areata;Alpers disease;Alveolar proteinosis;Ammonia
abnormal;Ammonia increased;Amniotic cavity
infection;Amygdalohippocampectomy;Amyloid
arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic
reaction;Anaphylactic shock;Anaphylactic transfusion
reaction;Anaphylactoid reaction;Anaphylactoid
shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic
neuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine
receptor antibody positive;Anti-actin antibody
positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia
antibody positive;Anti-cyclic citrullinated peptide antibody
positive;Anti-epithelial antibody positive;Anti-erythrocyte
antibody positive;Anti-exosome complex antibody positive;Anti-
GAD antibody negative;Anti-GAD antibody
positive;Anti-ganglioside antibody positive;Antigliadin antibody
positive;Anti-glomerular basement membrane antibody
positive;Anti-glomerular basement membrane
disease;Anti-glycyl-tRNA synthetase antibody positive;Anti-HLA
antibody test positive;Anti-IA2 antibody positive;Anti-insulin
antibody increased;Anti-insulin antibody positive;Anti-insulin
receptor antibody increased;Anti- insulin receptor antibody
positive;Anti-interferon antibody negative;Anti-interferon
antibody positive;Anti-islet cell antibody
positive;Antimitochondrial antibody positive;Anti-muscle
specific kinase antibody positive;Anti-myelin-associated
glycoprotein antibodies positive;Anti-myelin-associated
glycoprotein associated polyneuropathy;Antimyocardial antibody
positive;Anti-neuronal antibody positive;Antineutrophil
cytoplasmic antibody increased;Antineutrophil cytoplasmic
antibody positive;Anti-neutrophil cytoplasmic antibody positive
vasculitis;Anti-NMDA antibody positive;Antinuclear antibody
increased;Antinuclear antibody positive;Antiphospholipid
antibodies positive;Antiphospholipid syndrome;Anti-platelet
antibody positive;Anti-prothrombin antibody
positive;Antiribosomal P antibody positive;Anti-RNA polymerase
III antibody positive;Anti-saccharomyces cerevisiae antibody
test positive;Anti-sperm antibody positive;Anti-SRP antibody
positive;Antisynthetase syndrome;Anti-thyroid antibody
positive;Anti-transglutaminase antibody increased;Anti-VGCC
antibody positive;Anti- VGKC antibody positive;Anti-vimentin
antibody positive;Antiviral prophylaxis;Antiviral treatment;Anti-zinc
transporter 8 antibody positive;Aortic embolus;Aortic
thrombosis;Aortitis;Aplasia pure red cell;Aplastic
anaemia;Application site thrombosis;Application site
vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass
thrombosis;Arterial thrombosis;Arteriovenous fistula
thrombosis;Arteriovenous graft site stenosis;Arteriovenous graft
thrombosis;Arteritis;Arteritis
CONFIDENTIAL Page 1
FDA-CBER-2021-5683-0000083
Page 30
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event
Reports
coronary;Arthralgia;Arthritis;Arthritis
enteropathic;Ascites;Aseptic cavernous sinus
thrombosis;Aspartate aminotransferase abnormal;Aspartate
aminotransferase increased;Aspartate-glutamate-transporter
deficiency;AST to platelet ratio index increased;AST/ALT ratio
abnormal;Asthma;Asymptomatic COVID-
19;Ataxia;Atheroembolism;Atonic seizures;Atrial
thrombosis;Atrophic thyroiditis;Atypical benign partial
epilepsy;Atypical pneumonia [Note: This sounds like the original
definition of Covid-19 out of Wuhan]
Aura;Autoantibody
positive;Autoimmune anaemia;Autoimmune aplastic
anaemia;Autoimmune arthritis;Autoimmune blistering
disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune
demyelinating disease;Autoimmune dermatitis;Autoimmune
disorder;Autoimmune encephalopathy;Autoimmune endocrine
disorder;Autoimmune enteropathy;Autoimmune eye
disorder;Autoimmune haemolytic anaemia;Autoimmune
heparin-induced thrombocytopenia;Autoimmune hepatitis;Autoimmune
hyperlipidaemia;Autoimmune hypothyroidism;Autoimmune inner ear
disease;Autoimmune lung disease;Autoimmune lymphoproliferative
syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune
nephritis;Autoimmune neuropathy;Autoimmune
neutropenia;Autoimmune pancreatitis;Autoimmune
pancytopenia;Autoimmune pericarditis;Autoimmune
retinopathy;Autoimmune thyroid disorder;Autoimmune
thyroiditis;Autoimmune uveitis;Autoinflammation with infantile
enterocolitis;Autoinflammatory disease;Automatism
epileptic;Autonomic nervous system imbalance;Autonomic
seizure;Axial spondyloarthritis;Axillary vein thrombosis;Axonal
and demyelinating polyneuropathy;Axonal
neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band
sensation;Basedow's disease;Basilar artery
thrombosis;Basophilopenia;B-cell aplasia;Behcet's
syndrome;Benign ethnic neutropenia;Benign familial neonatal
convulsions;Benign familial pemphigus;Benign rolandic
epilepsy;Beta-2 glycoprotein antibody positive;Bickerstaff's
encephalitis;Bile output abnormal;Bile output decreased;Biliary
ascites;Bilirubin conjugated abnormal;Bilirubin conjugated
increased;Bilirubin urine present;Biopsy liver
abnormal;Biotinidase deficiency;Birdshot chorioretinopathy;Blood
alkaline phosphatase abnormal;Blood alkaline phosphatase
increased;Blood bilirubin abnormal;Blood bilirubin
increased;Blood bilirubin unconjugated increased;Blood
cholinesterase abnormal;Blood cholinesterase decreased;Blood
pressure decreased;Blood pressure diastolic decreased;Blood
pressure systolic decreased;Blue toe syndrome;Brachiocephalic
vein thrombosis;Brain stem embolism;Brain stem
thrombosis;Bromosulphthalein test abnormal;Bronchial
oedema;Bronchitis;Bronchitis mycoplasmal;Bronchitis
viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;Budd-
Chiari syndrome;Bulbar palsy;Butterfly rash;C1q
nephropathy;Caesarean section;Calcium
embolism;Capillaritis;Caplan's syndrome;Cardiac
amyloidosis;Cardiac arrest;Cardiac failure;Cardiac failure
acute;Cardiac sarcoidosis;Cardiac ventricular
thrombosis;Cardiogenic shock;Cardiolipin antibody
positive;Cardiopulmonary failure;Cardio-respiratory
arrest;Cardio-respiratory distress;Cardiovascular
insufficiency;Carotid arterial embolus;Carotid artery
thrombosis;Cataplexy;Catheter site thrombosis;Catheter site
vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency
disorder;CEC syndrome;Cement embolism;Central nervous system
lupus;Central nervous system vasculitis;Cerebellar artery
thrombosis;Cerebellar embolism;Cerebral amyloid
angiopathy;Cerebral arteritis;Cerebral artery embolism;Cerebral
artery thrombosis;Cerebral gas embolism;Cerebral
microembolism;Cerebral septic infarct;Cerebral
thrombosis;Cerebral venous sinus thrombosis;Cerebral venous
thrombosis;Cerebrospinal thrombotic
CONFIDENTIAL Page 2
FDA-CBER-2021-5683-0000084
Page
31
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis
of Post-authorization Adverse Event Reports
tamponade;Cerebrovascular accident;Change in seizure
presentation;Chest discomfort;Child- Pugh-Turcotte score
abnormal;Child-Pugh-Turcotte score
increased;Chillblains;Choking;Choking sensation;Cholangitis
sclerosing;Chronic autoimmune glomerulonephritis;Chronic
cutaneous lupus erythematosus;Chronic fatigue syndrome;Chronic
gastritis;Chronic inflammatory demyelinating
polyradiculoneuropathy;Chronic lymphocytic inflammation with
pontine perivascular enhancement responsive to steroids;Chronic
recurrent multifocal osteomyelitis;Chronic respiratory
failure;Chronic spontaneous urticaria;Circulatory
collapse;Circumoral oedema;Circumoral swelling;Clinically
isolated syndrome;Clonic convulsion;Coeliac disease;Cogan's
syndrome;Cold agglutinins positive;Cold type haemolytic
anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis
microscopic;Colitis ulcerative;Collagen disorder;Collagen-vascular
disease;Complement factor abnormal;Complement factor C1
decreased;Complement factor C2 decreased;Complement factor C3
decreased;Complement factor C4 decreased;Complement factor
decreased;Computerised tomogram liver abnormal;Concentric
sclerosis;Congenital anomaly;Congenital bilateral perisylvian
syndrome;Congenital herpes simplex infection;Congenital
myasthenic syndrome;Congenital varicella infection;Congestive
hepatopathy;Convulsion in childhood;Convulsions local;Convulsive
threshold lowered;Coombs positive haemolytic anaemia;Coronary
artery disease;Coronary artery embolism;Coronary artery
thrombosis;Coronary bypass thrombosis;Coronavirus
infection;Coronavirus test;Coronavirus test negative;Coronavirus
test positive;Corpus callosotomy;Cough;Cough variant
asthma;COVID-19;COVID-19 immunisation;COVID-19
pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial nerve
disorder;Cranial nerve palsies multiple;Cranial nerve
paralysis;CREST syndrome;Crohn's
disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal
band present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus
erythematosus;Cutaneous sarcoidosis;Cutaneous
vasculitis;Cyanosis;Cyclic neutropenia;Cystitis
interstitial;Cytokine release syndrome;Cytokine storm;De novo
purine synthesis inhibitors associated acute inflammatory
syndrome;Death neonatal;Deep vein thrombosis;Deep vein
thrombosis postoperative;Deficiency of bile secretion;Deja
vu;Demyelinating
polyneuropathy;Demyelination;Dermatitis;Dermatitis
bullous;Dermatitis herpetiformis;Dermatomyositis;Device
embolisation;Device related thrombosis;Diabetes
mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis
amyloidosis;Dialysis membrane reaction;Diastolic
hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated
intravascular coagulation;Disseminated intravascular coagulation
in newborn;Disseminated neonatal herpes simplex;Disseminated
varicella;Disseminated varicella zoster vaccine virus
infection;Disseminated varicella zoster virus infection;DNA
antibody positive;Double cortex syndrome;Double stranded DNA
antibody positive;Dreamy state;Dressler's syndrome;Drop
attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile
epileptic encephalopathy with burst-suppression;Eclampsia;Eczema
herpeticum;Embolia cutis medicamentosa;Embolic cerebellar
infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic
stroke;Embolism;Embolism arterial;Embolism
venous;Encephalitis;Encephalitis allergic;Encephalitis
autoimmune;Encephalitis brain stem;Encephalitis
haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post
immunisation;Encephalomyelitis;Encephalopathy;Endocrine
disorder;Endocrine ophthalmopathy;Endotracheal
intubation;Enteritis;Enteritis leukopenic;Enterobacter
pneumonia;Enterocolitis;Enteropathic
spondylitis;Eosinopenia;Eosinophilic
CONFIDENTIAL Page 3
FDA-CBER-2021-5683-0000085
Page 32
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis
of Post-authorization Adverse Event Reports
fasciitis;Eosinophilic granulomatosis with
polyangiitis;Eosinophilic
oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy
with myoclonic-atonic seizures;Epileptic aura;Epileptic
psychosis;Erythema;Erythema induratum;Erythema
multiforme;Erythema nodosum;Evans syndrome;Exanthema
subitum;Expanded disability status scale score
decreased;Expanded disability status scale score
increased;Exposure to communicable disease;Exposure to
SARS-CoV-2;Eye oedema;Eye pruritus;Eye swelling;Eyelid
oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial
dystonic seizure;Fat embolism;Febrile convulsion;Febrile
infection-related epilepsy syndrome;Febrile neutropenia;Felty's
syndrome;Femoral artery embolism;Fibrillary
glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal
cortical resection;Focal dyscognitive seizures;Foetal distress
syndrome;Foetal placental thrombosis;Foetor hepaticus;Foreign
body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes
mellitus;Galactose elimination capacity test abnormal;Galactose
elimination capacity test decreased;Gamma-glutamyltransferase
abnormal;Gamma-glutamyltransferase increased;Gastritis
herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised
onset non-motor seizure;Generalised tonic-clonic seizure;Genital
herpes;Genital herpes simplex;Genital herpes zoster;Giant cell
arteritis;Glomerulonephritis;Glomerulonephritis
membranoproliferative;Glomerulonephritis
membranous;Glomerulonephritis rapidly
progressive;Glossopharyngeal nerve paralysis;Glucose transporter
type 1 deficiency syndrome;Glutamate dehydrogenase
increased;Glycocholic acid increased;GM2
gangliosidosis;Goodpasture's syndrome;Graft
thrombosis;Granulocytopenia;Granulocytopenia
neonatal;Granulomatosis with polyangiitis;Granulomatous
dermatitis;Grey matter heterotopia;Guanase increased;Guillain-
Barre syndrome;Haemolytic anaemia;Haemophagocytic
lymphohistiocytosis;Haemorrhage;Haemorrhagic
ascites;Haemorrhagic disorder;Haemorrhagic
pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic
vasculitis;Hantavirus pulmonary infection;Hashimoto's
encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein
purpura;Henoch- Schonlein purpura nephritis;Hepaplastin
abnormal;Hepaplastin decreased;Heparin-induced
thrombocytopenia;Hepatic amyloidosis;Hepatic artery
embolism;Hepatic artery flow decreased;Hepatic artery
thrombosis;Hepatic enzyme abnormal;Hepatic enzyme
decreased;Hepatic enzyme increased;Hepatic fibrosis marker
abnormal;Hepatic fibrosis marker increased;Hepatic function
abnormal;Hepatic hydrothorax;Hepatic hypertrophy;Hepatic
hypoperfusion;Hepatic lymphocytic infiltration;Hepatic
mass;Hepatic pain;Hepatic sequestration;Hepatic vascular
resistance increased;Hepatic vascular thrombosis;Hepatic vein
embolism;Hepatic vein thrombosis;Hepatic venous pressure
gradient abnormal;Hepatic venous pressure gradient
increased;Hepatitis;Hepatobiliary scan
abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema
with C1 esterase inhibitor deficiency;Herpes dermatitis;Herpes
gestationis;Herpes oesophagitis;Herpes ophthalmic;Herpes
pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex
cervicitis;Herpes simplex colitis;Herpes simplex
encephalitis;Herpes simplex gastritis;Herpes simplex
hepatitis;Herpes simplex meningitis;Herpes simplex
meningoencephalitis;Herpes simplex meningomyelitis;Herpes
simplex necrotising retinopathy;Herpes simplex
oesophagitis;Herpes simplex otitis externa;Herpes simplex
pharyngitis;Herpes simplex pneumonia;Herpes simplex
reactivation;Herpes simplex sepsis;Herpes simplex
viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes
simplex visceral;Herpes virus
CONFIDENTIAL Page 4
FDA-CBER-2021-5683-0000086
Page 33
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event
Reports
infection;Herpes zoster;Herpes zoster cutaneous
disseminated;Herpes zoster infection neurological;Herpes zoster
meningitis;Herpes zoster meningoencephalitis;Herpes zoster
meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster
necrotising retinopathy;Herpes zoster oticus;Herpes zoster
pharyngitis;Herpes zoster reactivation;Herpetic
radiculopathy;Histone antibody positive;Hoigne's syndrome;Human
herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human
herpesvirus 6 infection reactivation;Human herpesvirus 7
infection;Human herpesvirus 8
infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia
benign monoclonal;Hyperglycaemic
seizure;Hypersensitivity;Hypersensitivity
vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H
ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve
paralysis;Hypoglossal nerve paresis;Hypoglycaemic
seizure;Hyponatraemic seizure;Hypotension;Hypotensive
crisis;Hypothenar hammer
syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4 lymphocytopenia;
[Note: sounds like "AIDS" except Fauci re-defined AIDS in 1993,
after the "Amsterdam Surprise" as only occurring when HIV was
"present" so all thousands the non HIV, "idiopathic CD4
lympho-cytopenia cases were excluded, creating a tautological
definition that came to be "HIV/AIDS." ] Idiopathic generalised
epilepsy;Idiopathic interstitial pneumonia;Idiopathic
neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM
nephropathy;IIIrd nerve paralysis;IIIrd nerve paresis;Iliac
artery embolism;Immune thrombocytopenia;Immune- mediated adverse
reaction;Immune-mediated cholangitis;Immune-mediated
cholestasis;Immune-mediated cytopenia;Immune-mediated
encephalitis;Immune-mediated encephalopathy;Immune-mediated
endocrinopathy;Immune-mediated enterocolitis;Immune- mediated
gastritis;Immune-mediated hepatic disorder;Immune-mediated
hepatitis;Immune- mediated hyperthyroidism;Immune-mediated
hypothyroidism;Immune-mediated myocarditis;Immune-mediated
myositis;Immune-mediated nephritis;Immune-mediated
neuropathy;Immune-mediated pancreatitis;Immune-mediated
pneumonitis;Immune-mediated renal disorder;Immune-mediated
thyroiditis;Immune-mediated uveitis;Immunoglobulin G4 related
disease;Immunoglobulins abnormal;Implant site
thrombosis;Inclusion body myositis;Infantile genetic
agranulocytosis;Infantile spasms;Infected vasculitis;Infective
thrombosis;Inflammation;Inflammatory bowel disease;Infusion site
thrombosis;Infusion site vasculitis;Injection site
thrombosis;Injection site urticaria;Injection site
vasculitis;Instillation site thrombosis;Insulin autoimmune
syndrome;Interstitial granulomatous dermatitis;Interstitial lung
disease;Intracardiac mass;Intracardiac thrombus;Intracranial
pressure increased;Intrapericardial thrombosis;Intrinsic factor
antibody abnormal;Intrinsic factor antibody positive;IPEX
syndrome;Irregular breathing;IRVAN syndrome;IVth nerve
paralysis;IVth nerve paresis;JC polyomavirus test positive;JC
virus CSF test positive;Jeavons syndrome;Jugular vein
embolism;Jugular vein thrombosis;Juvenile idiopathic
arthritis;Juvenile myoclonic epilepsy;Juvenile
polymyositis;Juvenile psoriatic arthritis;Juvenile
spondyloarthritis;Kaposi sarcoma inflammatory cytokine
syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma
blenorrhagica;Ketosis- prone diabetes mellitus;Kounis
syndrome;Lafora's myoclonic epilepsy;Lambl's
excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal
rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent
autoimmune diabetes in adults;LE cells present;Lemierre
syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase
increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia
neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen
planopilaris;Lichen planus;Lichen sclerosus;Limbic
encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver
function test abnormal;Liver function test decreased;Liver
function test increased;Liver induration;Liver injury;Liver iron
concentration abnormal;Liver iron concentration
CONFIDENTIAL Page 5
FDA-CBER-2021-5683-0000087
Page 34
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event
Reports
increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver
scan abnormal;Liver tenderness;Low birth weight baby;Lower
respiratory tract herpes infection;Lower respiratory tract
infection;Lower respiratory tract infection viral;Lung
abscess;Lupoid hepatic cirrhosis;Lupus cystitis;Lupus
encephalitis;Lupus endocarditis;Lupus enteritis;Lupus
hepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus
pancreatitis;Lupus pleurisy;Lupus pneumonitis;Lupus
vasculitis;Lupus-like syndrome;Lymphocytic
hypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC
syndrome;Magnetic resonance imaging liver abnormal;Magnetic
resonance proton density fat fraction measurement;Mahler
sign;Manufacturing laboratory analytical testing
issue;Manufacturing materials issue;Manufacturing production
issue;Marburg's variant multiple sclerosis;Marchiafava-Bignami
disease;Marine Lenhart syndrome;Mastocytic
enterocolitis;Maternal exposure during pregnancy;Medical device
site thrombosis;Medical device site vasculitis;MELAS
syndrome;Meningitis;Meningitis aseptic;Meningitis
herpes;Meningoencephalitis herpes simplex
neonatal;Meningoencephalitis herpetic;Meningomyelitis
herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test
positive;Mesangioproliferative glomerulonephritis;Mesenteric
artery embolism;Mesenteric artery thrombosis;Mesenteric vein
thrombosis;Metapneumovirus infection;Metastatic cutaneous
Crohn's disease;Metastatic pulmonary
embolism;Microangiopathy;Microembolism;Microscopic
polyangiitis;Middle East respiratory syndrome;Migraine-triggered
seizure;Miliary pneumonia;Miller Fisher syndrome;Mitochondrial
aspartate aminotransferase increased;Mixed connective tissue
disease;Model for end stage liver disease score abnormal;Model
for end stage liver disease score increased;Molar ratio of total
branched-chain amino acid to tyrosine;Molybdenum cofactor
deficiency;Monocytopenia;Mononeuritis;Mononeuropathy
multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya
disease;Multifocal motor neuropathy;Multiple organ dysfunction
syndrome;Multiple sclerosis;Multiple sclerosis relapse;Multiple
sclerosis relapse prophylaxis;Multiple subpial
transection;Multisystem inflammatory syndrome in
children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia
gravis crisis;Myasthenia gravis neonatal;Myasthenic
syndrome;Myelitis;Myelitis transverse;Myocardial
infarction;Myocarditis;Myocarditis post infection;Myoclonic
epilepsy;Myoclonic epilepsy and ragged-red
fibres;Myokymia;Myositis;Narcolepsy;Nasal herpes;Nasal
obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's
disease;Neonatal epileptic seizure;Neonatal lupus
erythematosus;Neonatal mucocutaneous herpes simplex;Neonatal
pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic
fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis
cranial;Neuromyelitis optica pseudo relapse;Neuromyelitis optica
spectrum disorder;Neuromyotonia;Neuronal neuropathy;Neuropathy
peripheral;Neuropathy, ataxia, retinitis pigmentosa
syndrome;Neuropsychiatric
lupus;Neurosarcoidosis;Neutropenia;Neutropenia
neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic
sepsis;Nodular rash;Nodular vasculitis;Noninfectious
myelitis;Noninfective encephalitis;Noninfective
encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary
embolism;Occupational exposure to communicable
disease;Occupational exposure to SARS-CoV-2;Ocular
hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular
sarcoidosis;Ocular vasculitis;Oculofacial
paralysis;Oedema;Oedema blister;Oedema due to hepatic
disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery
thrombosis;Ophthalmic herpes simplex;Ophthalmic herpes
zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic
CONFIDENTIAL Page 6
FDA-CBER-2021-5683-0000088
Page 35
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event
Reports
neuropathy;Optic perineuritis;Oral herpes;Oral lichen
planus;Oropharyngeal oedema;Oropharyngeal spasm;Oropharyngeal
swelling;Osmotic demyelination syndrome;Ovarian vein
thrombosis;Overlap syndrome;Paediatric autoimmune
neuropsychiatric disorders associated with streptococcal
infection;Paget-Schroetter syndrome;Palindromic
rheumatism;Palisaded neutrophilic granulomatous
dermatitis;Palmoplantar keratoderma;Palpable
purpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous
pneumonia;Paradoxical embolism;Parainfluenzae viral
laryngotracheobronchitis;Paraneoplastic
dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic
thrombosis;Paresis cranial nerve;Parietal cell antibody
positive;Paroxysmal nocturnal haemoglobinuria;Partial
seizures;Partial seizures with secondary generalisation;Patient
isolation;Pelvic venous thrombosis;Pemphigoid;Pemphigus;Penile
vein thrombosis;Pericarditis;Pericarditis lupus;Perihepatic
discomfort;Periorbital oedema;Periorbital swelling;Peripheral
artery thrombosis;Peripheral embolism;Peripheral
ischaemia;Peripheral vein thrombus extension;Periportal
oedema;Peritoneal fluid protein abnormal;Peritoneal fluid
protein decreased;Peritoneal fluid protein increased;Peritonitis
lupus;Pernicious anaemia;Petit mal epilepsy;Pharyngeal
oedema;Pharyngeal swelling;Pityriasis lichenoides et
varioliformis acuta;Placenta praevia;Pleuroparenchymal
fibroelastosis;Pneumobilia;Pneumonia;Pneumonia
adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes
viral;Pneumonia influenzal;Pneumonia measles;Pneumonia
mycoplasmal;Pneumonia necrotising;Pneumonia parainfluenzae
viral;Pneumonia respiratory syncytial viral;Pneumonia
viral;POEMS syndrome;Polyarteritis
nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune
syndrome type I;Polyglandular autoimmune syndrome type
II;Polyglandular autoimmune syndrome type III;Polyglandular
disorder;Polymicrogyria;Polymyalgia
rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic
progressive;Portal pyaemia;Portal vein embolism;Portal vein flow
decreased;Portal vein pressure increased;Portal vein
thrombosis;Portosplenomesenteric venous thrombosis;Post
procedural hypotension;Post procedural pneumonia;Post procedural
pulmonary embolism;Post stroke epilepsy;Post stroke seizure;Post
thrombotic retinopathy;Post thrombotic syndrome;Post viral
fatigue syndrome;Postictal headache;Postictal
paralysis;Postictal psychosis;Postictal state;Postoperative
respiratory distress;Postoperative respiratory
failure;Postoperative thrombosis;Postpartum
thrombosis;Postpartum venous thrombosis;Postpericardiotomy
syndrome;Post-traumatic epilepsy;Postural orthostatic
tachycardia syndrome;Precerebral artery
thrombosis;Pre-eclampsia;Preictal state;Premature
labour;Premature menopause;Primary amyloidosis;Primary biliary
cholangitis;Primary progressive multiple sclerosis;Procedural
shock;Proctitis herpes;Proctitis ulcerative;Product availability
issue;Product distribution issue;Product supply
issue;Progressive facial hemiatrophy;Progressive multifocal
leukoencephalopathy;Progressive multiple sclerosis;Progressive
relapsing multiple sclerosis;Prosthetic cardiac valve
thrombosis;Pruritus;Pruritus
allergic;Pseudovasculitis;Psoriasis;Psoriatic
arthropathy;Pulmonary amyloidosis;Pulmonary artery
thrombosis;Pulmonary embolism;Pulmonary fibrosis;Pulmonary
haemorrhage;Pulmonary microemboli;Pulmonary oil
microembolism;Pulmonary renal syndrome;Pulmonary
sarcoidosis;Pulmonary sepsis;Pulmonary thrombosis;Pulmonary
tumour thrombotic microangiopathy;Pulmonary vasculitis;Pulmonary
veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma
gangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation
leukopenia;Radiculitis
CONFIDENTIAL Page 7
FDA-CBER-2021-5683-0000089
Page 36
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event
Reports
brachial;Radiologically isolated syndrome;Rash;Rash
erythematous;Rash pruritic;Rasmussen encephalitis;Raynaud's
phenomenon;Reactive capillary endothelial
proliferation;Relapsing multiple sclerosis;Relapsing-remitting
multiple sclerosis;Renal amyloidosis;Renal arteritis;Renal
artery thrombosis;Renal embolism;Renal failure;Renal vascular
thrombosis;Renal vasculitis;Renal vein embolism;Renal vein
thrombosis;Respiratory arrest;Respiratory disorder;Respiratory
distress;Respiratory failure;Respiratory paralysis;Respiratory
syncytial virus bronchiolitis;Respiratory syncytial virus
bronchitis;Retinal artery embolism;Retinal artery
occlusion;Retinal artery thrombosis;Retinal vascular
thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal
vein thrombosis;Retinol binding protein
decreased;Retinopathy;Retrograde portal vein
flow;Retroperitoneal fibrosis;Reversible airways
obstruction;Reynold's syndrome;Rheumatic brain disease;Rheumatic
disorder;Rheumatoid arthritis;Rheumatoid factor
increased;Rheumatoid factor positive;Rheumatoid factor
quantitative increased;Rheumatoid lung;Rheumatoid neutrophilic
dermatosis;Rheumatoid nodule;Rheumatoid nodule
removal;Rheumatoid scleritis;Rheumatoid vasculitis;Saccadic eye
movement;SAPHO syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1
test negative;SARS-CoV-1 test positive;SARS-CoV-2 antibody
test;SARS-CoV-2 antibody test negative;SARS-CoV-2 antibody test
positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2
test;SARS- CoV-2 test false negative;SARS-CoV-2 test false
positive;SARS-CoV-2 test negative;SARS- CoV-2 test
positive;SARS-CoV-2 viraemia;Satoyoshi
syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma
associated digital ulcer;Scleroderma renal crisis;Scleroderma-like
reaction;Secondary amyloidosis;Secondary cerebellar
degeneration;Secondary progressive multiple sclerosis;Segmented
hyalinising vasculitis;Seizure;Seizure anoxic;Seizure
cluster;Seizure like phenomena;Seizure prophylaxis;Sensation of
foreign body;Septic embolus;Septic pulmonary embolism;Severe
acute respiratory syndrome;Severe myoclonic epilepsy of
infancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt
thrombosis;Silent thyroiditis;Simple partial seizures;Sjogren's
syndrome;Skin swelling;SLE arthritis;Smooth muscle antibody
positive;Sneezing;Spinal artery embolism;Spinal artery
thrombosis;Splenic artery thrombosis;Splenic embolism;Splenic
thrombosis;Splenic vein
thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous
heparin-induced thrombocytopenia syndrome;Status
epilepticus;Stevens-Johnson syndrome; [Note: This, SJS, can
result in the skin coming off the body altogether, from the
body's attempt to rid itself of poison.] Stiff leg
syndrome;Stiff person syndrome;Stillbirth;Still's disease;Stoma
site thrombosis;Stoma site vasculitis;Stress
cardiomyopathy;Stridor;Subacute cutaneous lupus
erythematosus;Subacute endocarditis;Subacute inflammatory
demyelinating polyneuropathy;Subclavian artery
embolism;Subclavian artery thrombosis;Subclavian vein
thrombosis;Sudden unexplained death in epilepsy;Superior
sagittal sinus thrombosis;Susac's syndrome;Suspected COVID-
19;Swelling;Swelling face;Swelling of eyelid;Swollen
tongue;Sympathetic ophthalmia;Systemic lupus
erythematosus;Systemic lupus erythematosus disease activity
index abnormal;Systemic lupus erythematosus disease activity
index decreased;Systemic lupus erythematosus disease activity
index increased;Systemic lupus erythematosus rash;Systemic
scleroderma;Systemic sclerosis
pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal
lobe epilepsy;Terminal ileitis;Testicular autoimmunity;Throat
tightness;Thromboangiitis
obliterans;Thrombocytopenia;Thrombocytopenic
purpura;Thrombophlebitis;Thrombophlebitis
migrans;Thrombophlebitis
CONFIDENTIAL Page 8
FDA-CBER-2021-5683-0000090
Page 37
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event
Reports
neonatal;Thrombophlebitis septic;Thrombophlebitis
superficial;Thromboplastin antibody
positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in
device;Thrombosis mesenteric vessel;Thrombotic cerebral
infarction;Thrombotic microangiopathy;Thrombotic
stroke;Thrombotic thrombocytopenic purpura;Thyroid
disorder;Thyroid stimulating immunoglobulin
increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue
oedema;Tonic clonic movements;Tonic convulsion;Tonic
posturing;Topectomy;Total bile acids increased;Toxic epidermal
necrolysis;Toxic leukoencephalopathy;Toxic oil syndrome;Tracheal
obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis
mycoplasmal;Tracheobronchitis viral;Transaminases
abnormal;Transaminases increased;Transfusion-related alloimmune
neutropenia;Transient epileptic amnesia;Transverse sinus
thrombosis;Trigeminal nerve paresis;Trigeminal
neuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous
sclerosis complex;Tubulointerstitial nephritis and uveitis
syndrome;Tumefactive multiple sclerosis;Tumour embolism;Tumour
thrombosis;Type 1 diabetes mellitus;Type I hypersensitivity;Type
III immune complex mediated reaction;Uhthoff's
phenomenon;Ulcerative keratitis;Ultrasound liver
abnormal;Umbilical cord thrombosis;Uncinate
fits;Undifferentiated connective tissue disease;Upper airway
obstruction;Urine bilirubin increased;Urobilinogen urine
decreased;Urobilinogen urine increased;Urticaria;Urticaria
papular;Urticarial vasculitis;Uterine
rupture;Uveitis;Vaccination site thrombosis;Vaccination site
vasculitis;Vagus nerve paralysis;Varicella;Varicella
keratitis;Varicella post vaccine;Varicella zoster
gastritis;Varicella zoster oesophagitis;Varicella zoster
pneumonia;Varicella zoster sepsis;Varicella zoster virus
infection;Vasa praevia;Vascular graft thrombosis;Vascular
pseudoaneurysm thrombosis;Vascular purpura;Vascular stent
thrombosis;Vasculitic rash;Vasculitic
ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis
necrotising;Vena cava embolism;Vena cava thrombosis;Venous
intravasation;Venous recanalisation;Venous thrombosis;Venous
thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis
neonatal;Vertebral artery thrombosis;Vessel puncture site
thrombosis;Visceral venous thrombosis;VIth nerve paralysis;VIth
nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord
paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic
anaemia;Wheezing;White nipple sign;XIth nerve paralysis;X-ray
hepatobiliary abnormal;Young's syndrome;Zika virus associated
Guillain Barre syndrome.
[It goes on from there...]
Another story for another
time.
I consider it a privilege to have you, and I don't believe there are
"journalists" and civilians. I believe "journalists" are a relic of
a bygone era, and many people who don't identify as journalists are
doing the best reporting.
I haven't been employed
as a journalist for a very long time, for obvious reasons.
Substack is the dawn of a new
era, and for me, a beautiful lifeboat...
|
